Maker —
No US authorization
Decision—Studies450Trials49
Restylane Silk — FDA approval record and published evidence
Q-Med AB · Injectables · Hyaluronic acid filler
PMA · approvedP040024
PathwayPathwayA PMA is a premarket approval. FDA reviewed the manufacturer's own clinical evidence and approved the product for the indication it reviewed. It is an approval, and it covers that specific product and indication.
Methodology →PMA · approved
Methodology →PMA · approved
ClassClassThe FDA classification record for this product's code was not fetched, so the class is not transcribed here.
Methodology →—
Methodology →—
First approved2014
Years on marketYears on marketDerived: the data run date minus the first matched FDA decision date. Arithmetic on a real date, nothing else.
Methodology →12
Methodology →12
StudiesStudiesPubMed records for a fixed query about the MODALITY, not the brand. It measures how much has been published about a technique. It is not a quality score, not an efficacy measure, not a count of randomised trials, and not comparable between modalities of different ages. It says nothing about this brand specifically.
Methodology →1,298
Methodology →1,298
TrialsTrialsClinicalTrials.gov studies for a fixed query about the MODALITY, not the brand. Registration is not completion, not publication and not a result. Counts include studies of any status, size or sponsor, and the recruiting figure is a snapshot taken on the run date. Device studies are under-registered relative to drug studies.
Methodology →46
Methodology →46
A PMA product is approved, not cleared — FDA read the maker's own evidence. What this measuresA PMA is a premarket approval. FDA reviewed the manufacturer's own clinical evidence and approved the product for the indication it reviewed. It is an approval, and it covers that specific product and indication. It measures how much has been published about a technique. It is not a quality score, not an efficacy measure, not a count of randomised trials, and not comparable between modalities of different ages. It says nothing about this brand specifically.
Methodology →
Compare with similar
Belotero Balance
Belotero Intense (+) Lidocaine
Belotero Volume (+) Lidocaine
Compare all 4 →
Shares treatment areas — not a recommendation. What this measuresPicked mechanically, by rule and nothing else: products in the same Index category that share the most derived treatment areas with this one, ties broken alphabetically. Treatment areas are themselves derived by a published keyword rule run over a real source string, not copied from the cleared or approved indication, so a shared area means two products' source strings happened to use the same word. It does not mean the two products do the same job, it is not a claim that they are interchangeable, and it is not a recommendation.
Methodology →
Overview
- Modality
- Hyaluronic acid filler
- Manufacturer
- Q-Med AB
- Category
- Injectables
- Latest decision
- FDA records
- 25
- Mapping
- Verified
Mapping is the weakest link on this page; the rule is published. What this measures25 openFDA PMA record(s) match. Records were selected by fetching every openFDA PMA record filed under P040024 (limit=1000, the complete supplement set) and keeping those whose trade_name contains 'restylane silk' once accents and punctuation are folded away. Folding is required because FDA writes the registered mark inline on many supplements ("Restylane® Defyne", "Juvéderm® Ultra XC"), and a literal phrase search silently skips those records. openFDA holds NO original PMA record under this trade name -- every match is a supplement to P040024 -- so first_decision_date is the earliest SUPPLEMENT that names this brand, not an original FDA approval date. P040024 carries 133 records in total; 25 of them name this brand. Sibling products approved under the same PMA are carded separately and are not deduplicated by PMA number. A mapping is the weakest link on this page: if it is wrong, every number above it is about the wrong product. It is stated in full so it can be checked.
Methodology →
Regulatory
| Identifier | Type | Role | FDA record |
|---|---|---|---|
| P040024 | PMA — approved | Primary | Open → |
| Code | FDA device name | 21 CFR |
|---|---|---|
| LMH | — | — |
Approved indication: not transcribed here — read it on P040024 → Approved indicationopenFDA's release of this database does not return the indications-for-use text, and this Index will not paraphrase a regulatory statement it has not transcribed. A PMA is a premarket approval. FDA reviewed the manufacturer's own clinical evidence and approved the product for the indication it reviewed. It is an approval, and it covers that specific product and indication.
Methodology →
Evidence
Counted for the modality, never the brand.
1,298PubMed, all time
1,033PubMed, 10y
46Studies
3Recruiting
| Hyaluronic acid filler | |
|---|---|
| 2016 | 44 |
| 2017 | 55 |
| 2018 | 64 |
| 2019 | 80 |
| 2020 | 110 |
| 2021 | 119 |
| 2022 | 114 |
| 2023 | 128 |
| 2024 | 164 |
| 2025 | 196 |
| 2026 | 120 |
196papers · 2025 · modality, not brand+20%
PubMed counts publications; ClinicalTrials.gov counts registrations. Neither is a quality score. What this measuresPubMed record counts and ClinicalTrials.gov study counts for a fixed query about the MODALITY, never the brand. It measures how much has been published about a technique. It is not a quality score, not an efficacy measure, not a count of randomised trials, and not comparable between modalities of different ages. It says nothing about this brand specifically. Registration is not completion, not publication and not a result. Counts include studies of any status, size or sponsor, and the recruiting figure is a snapshot taken on the run date. Device studies are under-registered relative to drug studies. The same counts apply to every other product in the Index on this modality: Belotero Balance, Belotero Intense (+) Lidocaine, Belotero Volume (+) Lidocaine, Juvederm Ultra XC, Juvederm Volbella XC, Juvederm Vollure XC, Juvederm Voluma XC, Juvederm Volux XC, Profhilo, RHA Collection, Restylane Defyne, Restylane Kysse, Restylane Lyft, Revanesse Versa, SKINVIVE by Juvederm. The trend line is the same fixed modality query windowed per publication year. Number of PubMed records matching each modality's fixed, hand-written title/abstract query, windowed to a single publication year. It measures publication volume about a TECHNIQUE, not a brand. It is NOT a quality score, NOT an efficacy measure, and NOT a count of randomised trials. 2026 is a partial year (run date 2026-07-26); its bar is short because the year is short, not because interest fell. 2026 contains only papers indexed by the run date (2026-07-26). Render it visually distinct (e.g. hollow/hatched) or annotate it; never let it read as a decline.
Methodology →
PubMed query, verbatim
("hyaluronic acid filler"[tiab] OR "hyaluronic acid dermal filler"[tiab] OR ("hyaluronic acid"[tiab] AND ("dermal filler"[tiab] OR "soft tissue filler"[tiab] OR "nasolabial"[tiab] OR "lip augmentation"[tiab] OR "midface"[tiab]))) AND (aesthetic[tiab] OR cosmetic[tiab] OR facial[tiab] OR skin[tiab] OR volume[tiab])
ClinicalTrials.gov query, verbatim
intervention: ("hyaluronic acid filler" OR "hyaluronic acid dermal filler" OR "HA filler") condition: ("nasolabial folds" OR "facial wrinkles" OR "lip augmentation" OR "volume deficit" OR cosmetic)
Treatment areas
What matched, and where
| Area | Matched term | Source string |
|---|---|---|
| Wrinkles & lines | wrinkle | ClinicalTrials.gov condition query for Hyaluronic acid filler |
| Volume & folds | nasolabial fold | ClinicalTrials.gov condition query for Hyaluronic acid filler |
Derived by keyword rule, not the cleared or approved indication. What this measuresTreatment areas are DERIVED, not copied from an FDA field. A fixed keyword list is run over two real strings: the ClinicalTrials.gov condition query actually executed for this product's modality on the run date, and the device names of the FDA product codes attached to this product's records. The words "skin" and "cosmetic" are ignored because every query contains one of them. An area is not the cleared or approved indication — openFDA's 510(k) response does not carry the indications-for-use text, and this Index does not paraphrase it.
Methodology →
Sources
- openFDA query run for this producthttps://api.fda.gov/device/pma.json?search=pma_number:%22P040024%22&limit=1000
- openFDA query run for this producthttps://api.fda.gov/device/classification.json?search=product_code:%22LMH%22&limit=1
- FDA public record for P040024https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040024
- PubMed count, all timehttps://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&retmode=json&rettype=count&term=%28%22hyaluronic%20acid%20filler%22%5Btiab%5D%20OR%20%22hyaluronic%20acid%20dermal%20filler%22%5Btiab%5D%20OR%20%28%22hyaluronic%20acid%22%5Btiab%5D%20AND%20%28%22dermal%20filler%22%5Btiab%5D%20OR%20%22soft%20tissue%20filler%22%5Btiab%5D%20OR%20%22nasolabial%22%5Btiab%5D%20OR%20%22lip%20augmentation%22%5Btiab%5D%20OR%20%22midface%22%5Btiab%5D%29%29%29%20AND%20%28aesthetic%5Btiab%5D%20OR%20cosmetic%5Btiab%5D%20OR%20facial%5Btiab%5D%20OR%20skin%5Btiab%5D%20OR%20volume%5Btiab%5D%29
- PubMed count, last 10 yearshttps://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&retmode=json&rettype=count&term=%28%22hyaluronic%20acid%20filler%22%5Btiab%5D%20OR%20%22hyaluronic%20acid%20dermal%20filler%22%5Btiab%5D%20OR%20%28%22hyaluronic%20acid%22%5Btiab%5D%20AND%20%28%22dermal%20filler%22%5Btiab%5D%20OR%20%22soft%20tissue%20filler%22%5Btiab%5D%20OR%20%22nasolabial%22%5Btiab%5D%20OR%20%22lip%20augmentation%22%5Btiab%5D%20OR%20%22midface%22%5Btiab%5D%29%29%29%20AND%20%28aesthetic%5Btiab%5D%20OR%20cosmetic%5Btiab%5D%20OR%20facial%5Btiab%5D%20OR%20skin%5Btiab%5D%20OR%20volume%5Btiab%5D%29%20AND%20%28%222016%2F01%2F01%22%5Bdp%5D%20%3A%20%222026%2F12%2F31%22%5Bdp%5D%29
- ClinicalTrials.gov, all studieshttps://clinicaltrials.gov/api/v2/studies?query.intr=%28%22hyaluronic%20acid%20filler%22%20OR%20%22hyaluronic%20acid%20dermal%20filler%22%20OR%20%22HA%20filler%22%29&query.cond=%28%22nasolabial%20folds%22%20OR%20%22facial%20wrinkles%22%20OR%20%22lip%20augmentation%22%20OR%20%22volume%20deficit%22%20OR%20cosmetic%29&countTotal=true&pageSize=1&fields=NCTId
- ClinicalTrials.gov, recruiting onlyhttps://clinicaltrials.gov/api/v2/studies?query.intr=%28%22hyaluronic%20acid%20filler%22%20OR%20%22hyaluronic%20acid%20dermal%20filler%22%20OR%20%22HA%20filler%22%29&query.cond=%28%22nasolabial%20folds%22%20OR%20%22facial%20wrinkles%22%20OR%20%22lip%20augmentation%22%20OR%20%22volume%20deficit%22%20OR%20cosmetic%29&filter.overallStatus=RECRUITING&countTotal=true&pageSize=1&fields=NCTId
No adverse-event data is published anywhere on this site. What this measuresNo adverse-event data appears anywhere on this site. MAUDE and FAERS were never queried: those counts have no denominator, reporting is voluntary and duplicated, and a report is not evidence of causation. Publishing them beside a brand name would mislead.
Methodology →